| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.23544 |
| P698 | PubMed publication ID | 18470908 |
| P50 | author | Isabella Sperduti | Q37383620 |
| Diana Giannarelli | Q44736865 | ||
| Emilio Bria | Q46978152 | ||
| P2093 | author name string | Paolo Carlini | |
| Michele Milella | |||
| Francesco Cognetti | |||
| Alessandra Felici | |||
| Cecilia Nisticò | |||
| Edmondo Terzoli | |||
| Federica Cuppone | |||
| P2860 | cites work | Cancer statistics, 2007 | Q29547293 |
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 | ||
| Preoperative (neoadjuvant) systemic treatment of breast cancer | Q36274474 | ||
| HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. | Q38302227 | ||
| Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer | Q38446760 | ||
| Confidence intervals for the number needed to treat | Q42759158 | ||
| Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial | Q44218912 | ||
| The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. | Q44618276 | ||
| Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study | Q46463193 | ||
| Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. | Q46817262 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. | Q53256954 | ||
| Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). | Q53396920 | ||
| Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. | Q54073250 | ||
| Interpreting Measures of Treatment Effect in Cancer Clinical Trials | Q56020813 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
| Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma | Q61900024 | ||
| Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 | Q73494751 | ||
| Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute | Q74082953 | ||
| Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy | Q74611825 | ||
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 | ||
| Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women | Q77435888 | ||
| Global gene expression changes during neoadjuvant chemotherapy for human breast cancer | Q78714471 | ||
| Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome | Q80548327 | ||
| American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome | Q80996920 | ||
| Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer | Q81179376 | ||
| Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study | Q81228339 | ||
| Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis | Q81353372 | ||
| Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27 | Q83137320 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 238-246 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials | |
| P478 | volume | 113 |
| Q24186323 | Adjuvant therapy for resected pancreatic cancer |
| Q94327146 | Adjuvant therapy for resected pancreatic cancer |
| Q36976929 | Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer |
| Q37787119 | Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer |
| Q35537059 | Development of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models |
| Q64967432 | Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer. |
| Q47713074 | From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer |
| Q53618240 | Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. |
| Q37802823 | Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer |
| Q34138174 | NEO adjuvant chemotherapy in breast cancer: What have we learned so far? |
| Q37145188 | Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future |
| Q55466335 | Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. |
| Q38744407 | New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles. |
| Q90247672 | Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer |
| Q91619867 | Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) |
| Q53455845 | Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer |
| Q86933946 | Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy |
| Q38157648 | Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer |
| Q38711217 | Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review |
| Q37743510 | Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel |
| Q34048154 | The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells |
| Q34555411 | Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer |
Search more.